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absent circulating basophils identified
previously (Grattan et al., 1997). It is
therefore of interest that the mean level
of anti-FceRIa detected by immunoen-
zymatic assay was substantially and
significantly higher than other chronic
urticaria patients with enough circulat-
ing basophils to assess responsiveness
to anti-IgE. This would support the
possibility that the level of autoanti-
body may be a factor in determining
functionality. Testing chronic urticaria
basophil responsiveness to a monoclo-
nal anti-FceRIa in addition to anti-IgE
would seem appropriate in the
context of defining basophil phenotypes
in a disease that is believed to be caused
by both. Debate about the importance of
autoantibodies in urticaria pathogenesis
will no doubt continue but it is impor-
tant not to be side-lined from the
autoimmune hypothesis on the strength
of work that only shows part of a much
wider portfolio of clinical and laboratory
evidence supporting the concept.
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TO THE EDITOR
We appreciate the comments by Dr
Grattan and Dr Brozova to our article
(Eckman et al., 2008) concerning blood
basophil phenotypes and their relation-
ship to autoantibodies in patients with
chronic idiopathic urticaria (CIU).
However, we would like to respond to
their comments.
Grattan stated, ‘‘Unfortunately the
histamine releasing activity of sera was
not assessed by Eckman et aly’’ We
have three main concerns with hista-
mine-releasing activity (HRA). First, the
reliance on a normal basophil donor is
a major concern given the literature’s
demonstration of significant differences
in HRA results depending on who is
chosen as the basophil donor (Grattan
et al., 1991; Kikuchi and Kaplan, 2001).
Second, the reagents and methods are
not standardized, and they differ with
regard to the basophil isolation method,
the ratio of CIU sera to donor basophils,
the use of IL-3 as a basophil enhancer,
and the interpretation and variability
(poor replication) of a positive results
(Vonakis and Saini, 2005). Furthermore,
verification of HRA’s specificity for
autoantibodies by preincubating a CIU
patients sera with soluble FceRIa and
observing a reduction in HRA are
sparse and shown for only selected
datasets. HRA’s specificity is shown by
preincubating the IgG fraction of CIU
patients sera with soluble FceRIa and
then showing a subsequent reduction in
HRA in comparison to a sham control.
Hide et al. only show this inhibition in
4/17 patients, Kikuchi and Kaplan only
show inhibition in 7/111 patients, and
Fiebiger et al. in 9/50 patients (com-
plete sera; IgG fraction not isolated;
Hide et al., 1993; Fiebiger et al., 1998;
Kikuchi and Kaplan, 2001). The inhibi-
tion profiles in these studies are
significantly different. In addition,
Fiebiger showed 9 HRA-negative/
Abbreviation: CIU, chronic idiopathic urticaria; CIU R, CIU responder; CIU NR, CIU non-responder;
HRA, histamine releasing activity
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immunoenzymetric assay-positive sub-
jects had enhancement (rather than
inhibition) in HRA when sera were
preincubated with soluble FceRIa (Fie-
biger et al., 1998). Therefore, this test’s
ability to reproducibly and specifically
detect functional autoantibodies (versus
another serological factor) is limited in
our opinion. In addition, if ‘‘local tissue
concentrations of autoantibody rather
than circulating plasma concentrations
may determine whether sufficient
receptors can be cross-linked or not to
initiate degranulation’’, then serum
HRA is flawed in that it reflects serum
concentrations of a factor. Therefore,
we focused on a reproducible
immunoenzymetric assay to detect
autoantibodies.
Grattan questions our use of the term
‘‘idiopathic’’ urticaria. The term ‘‘auto-
immune’’ remains dependent on the
use of the highly variable HRA assay as
described above. Until tests to more
accurately define autoimmunity are
developed, we feel compelled to use
the term ‘‘idiopathic’’.
Grattan stated, ‘‘The key to under-
standing the etiology of urticaria is what
stimulates degranulation of the cuta-
neous mast cells, rather than circulating
basophilsy’’ We do not argue that the
cutaneous mast cell is central to the
pathology in CIU disease. However, a
role for blood basophils in CIU is
supported by a number of findings,
some of which are noted by Grattan in
previous publications. Blood basopenia
in active CIU has been described for
decades (Grattan, 2001). Blood baso-
philia is inversely correlated with urti-
carial disease activity (Grattan et al.,
2003). In CIU lesional sites, intradermal
basophils are also increased compared
to healthy, nonatopic control patients
(Ying et al., 2002). In CIU, short-term
use of corticosteroids is effective in
controlling flares of CIU (Sabroe and
Greaves, 2006), yet it does not affect
skin mast cell histamine release
(Schwiebert et al., 1996). In addition,
basophil numbers increase after treat-
ment with oral corticosteroids whereas
they decrease in non-CIU subjects; this
finding suggests an impairment of ba-
sophil recruitment to the skin (Grattan
et al., 2003). In summary, as noted by
Grattan and in his words, these findings
support the idea that basophils ‘‘may
contribute directly to the pathogenesis
of urticarial wheals in ‘‘idiopathic’’
urticaria’’ (Grattan, 2001).
Our approach to understanding the
role that a particular ‘‘factor’’ plays in
the etiology of CIU is to evaluate
differences in the presence, level or
structure of the ‘‘factor’’ or its target
during active disease as compared to
disease remission. In active CIU
disease, suppressed IgE receptor-
mediated histamine degranulation by
blood basophils has been observed by
several investigators (Greaves et al.,
1974; Kern and Lichtenstein, 1976;
Sabroe et al., 1998; Luquin et al.,
2005; Vonakis et al., 2007). In our
current study, we found a significant
increase in CIU patients basophils’ IgE-
receptor mediated degranulation
mediated by a polyclonal anti-IgE in 6
out of 6 patients in CIU disease remis-
sion (Figure 4a, Eckman et al., 2008),
and since publication, we have ob-
served another CIU patient enter remis-
sion with a similar dramatic rise in
basophil IgE-receptor mediated degra-
nulation (0–56%). Likewise, Kern and
Lichtenstein (1976) showed similar
changes in 5 out of 5 patients. Grattan
suggests that testing basophil respon-
siveness to a monoclonal anti-FceRIa in
addition to anti-IgE should be per-
formed; however, previous studies have
shown that in CIU patients, basophil
receptor-mediated degranulation to
anti-IgE is similar to anti-FceRIa (Sabroe
et al., 1998). As onlyB40% of patients
with CIU are thought to have ‘‘func-
tional’’ serum autoantibodies (IgG
anti-FceRIa and/or anti-IgE; Ferrer and
Kaplan, 2007), it is highly unlikely that
all 12 patients (6 from Eckman et al., 1
additional from our ongoing experi-
ence, and 5 from Kern and Lichtenstein)
with suppressed basophil degranulation
possessed functional autoantibodies,
yet all 12 patients showed increases in
their basophil histamine release profile
during disease remission. This observa-
tion may not only indicate a disease
related suppressive serological factor
beyond autoantibodies, but also
suggests that basophil function is tied
to CIU disease severity and is indepen-
dent of autoantibody status or presence.
We would like to briefly reply to
several other criticisms of our paper.
Grattan suggested that ‘‘complement’’,
‘‘subclass of IgG’’, and ‘‘conditional
autoimmunity’’ are ‘‘additional factors’’
that may make the autoantibodies
functional. Although a role for comple-
ment dependence for serum HRA is
provided by in vitro studies, it has yet to
be firmly established in vivo (Fiebiger
et al., 1998; Kikuchi and Kaplan, 2002).
Fiebiger et al. (1998) examined the IgG
subclasses of detected IgG anti-FceRIa.
The IgG1 and/or IgG3 subclasses were
the more prevalent subclasses of IgG
anti-FceRIa detected in the serum of
CIU subjects (91% of IgG anti-FceRIa)
as compared to subjects with other skin
diseases (44%; Fiebiger et al., 1998).
However, the relationship is far from
perfect and is likely only a partial
explanation for the presence of ‘‘non-
functioning’’ autoantibodies in non-
CIU subjects. As we mentioned, the
accurate quantification of the subclass
distribution of IgG autoantibodies is an
arduous task because of the lack of
subclass-specific standards for the anti-
bodies of interest and different binding
constants for the different subclass
detection antibodies (Hamilton, 1987).
Conditional autoimmunity is a theory
that states the functionality of autoanti-
bodies depends on the receptor occu-
pancy by IgE under the control of local
environmental influences (Miescher
et al., 2001). This theory lacks direct
experimental evidence in CIU.
In summary, we have shown for the
first time that basophil phenotypes
among CIU patients (CIU R and CIU
NR) appear independent of immunoen-
zymetric assay measured IgG anti-
FceRIa and IgG anti-IgE antibodies. In
addition, these phenotypes are stable
during active disease. Finally, similar to
the finding of Kern and Lichtenstein, we
found an enhancement in IgE-receptor
mediated degranulation in disease re-
mission. Collectively, the data support
a direct role of basophils in contributing
to CIU’s pathogenesis. Greater insight
into CIU may be gained from future
studies examining basophils/mast cells
or serological factors as they relate to
active disease and again in remission.
At the present time, available assays for
autoimmunity are flawed and do not
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consistently assist clinicians in their
understanding of CIU’s pathogenesis.
What is truly needed is a reproducible
assay to advance the specific definition
of autoimmune urticaria.
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TO THE EDITOR
The goal of this study is to gain insight
into putative pathways by which 13-cis
retinoic acid (13-cisRA) improves
acne by comparing the temporal
changes in gene expression in the skin
of acne patients. Gene array analysis
and immunohistochemistry were
performed on skin biopsies from
patients at baseline and after 8 weeks
of isotretinoin therapy and compared to
data obtained at 1 week (Nelson et al.,
2008).
As 13-cisRA drastically decreases
sebaceous gland size after 16 weeks
(Goldstein et al., 1982); we chose an 8-
week time point to examine changes in
skin histology and gene expression. All
protocols were approved by the Institu-
tional Review Board of The Pennsylva-
nia State University College of
Medicine and were conducted accord-
ing to the principles outlined in the
Declaration of Helsinki. Eight patients
who were prescribed isotretinoin for
their severe acne enrolled in the study
after giving informed consent and
5-mm punch biopsies of uninvolved
skin were taken from their upper backs
at baseline and 8 weeks of treatment.
Demographic data are presented in
Figure 1a. After 8 weeks, sebaceous
gland size was reduced by 76% (4.17-
fold) compared to baseline (P¼0.009)
(Figure 1b and d). At 1 week, glands
were decreased by approximately 49%
(not significant; Figure 1c and d).
Gene array expression analysis was
performed on biopsies at baseline and
after 8 weeks of therapy. Using a false
discovery rate of 0.05 corresponding toAbbreviation: 13-cisRA, 13-cis retinoic acid
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Temporal Changes in Gene Expression
